OREX News Alert Orexigen Therapeutics (OREX) 5.55 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 3:08 AM

Orexigen Therapeutics (OREX) 5.55 $OREX

Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)

Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:30PM CST
Orexigen Therapeutics (OREX) announced encouraging updates on its weight loss drug, Mysimba
BIIB: 391.66 (-0.45), OREX: 5.55 (+0.10), ALNY: 95.54 (+1.67)

Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

European Decision On Orexigen Gets Delayed Until March, But Approval Is Likely
Spencer Osborne - at Seeking Alpha - Mon Feb 09, 1:47PM CST

OREX: 5.55 (+0.10)

Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)

Orexigen Provides Progress Update on Mysimba European Marketing Authorization
PR Newswire - Mon Feb 09, 7:00AM CST
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced an update on the European marketing authorization application (MAA) for Mysimba(TM) (naltrexone HCl / bupropion HCl prolonged release) which is being reviewed for use as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (greater-than or equal to 18 years) with an initial Body Mass Index (BMI) of greater-than or equal to 30 kg/m2 (obese), or greater-than or equal to 27 kg/m2 to Ëe 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
OREX: 5.55 (+0.10)

Vivus' Qsymia Headed In The Wrong Direction
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 4:44AM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Orexigen: Contrave Script Sales Dip. Why?
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:36PM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Arena Scripts Grow, But Pace Is Slower Than Needed
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:31PM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Orexigen Therapeutics to Speak at the Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will participate in a fireside chat discussion at the Leerink Global Healthcare Conference in New York. The discussion is scheduled for Thursday, February 12th at 1:00 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investors section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.55 (+0.10)

Arena's Belviq Keeps Up Momentum During A Flat Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 3:05PM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Orexigen's Contrave Prescription Growth Slowing, But Still Good
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 5:37PM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Arena Pharmaceuticals' Belviq Set To Surge In 2015
Jim Roof - at Seeking Alpha - Mon Feb 02, 12:47PM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Orexigen: Contrave Scripts Slow Down - Competition Lowers Price
Spencer Osborne - at Seeking Alpha - Mon Feb 02, 12:05PM CST

OREX: 5.55 (+0.10), ARNA: 4.55 (+0.02)

Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), HWAY: 21.32 (+0.01), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Arena's Belviq Conquers MLK Week According To Symphony
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 7:38AM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST

ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), ETRM: 1.21 (+0.06), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Arena - Flat Scripts Is Not A Good Start To 2015
Spencer Osborne - at Seeking Alpha - Tue Jan 27, 4:15PM CST

OREX: 5.55 (+0.10), ARNA: 4.55 (+0.02)

Contrave Scripts Continue Increases For Orexigen
Spencer Osborne - at Seeking Alpha - Tue Jan 27, 2:33PM CST

OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST

ZFGN: 39.06 (+0.92), OREX: 5.55 (+0.10), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Masimo's smartSET™ Revolutionizes Patient Monitoring

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Innventure Faces Major Lawsuit Over Misleading Investors

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Hyliion Class Action Deadline Nears for Investors

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Weifang's Cultural Resurgence: A Global Epigraphy Fest

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

LG OLED evo W6: UAE Roadshow Starts with a Bang

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Voter Events by Valley Community Healthcare Aim to Empower

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

AEVEX Facing Class Action Deadline Amid Stock Turmoil

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...